JP2014511844A5 - - Google Patents

Download PDF

Info

Publication number
JP2014511844A5
JP2014511844A5 JP2014501659A JP2014501659A JP2014511844A5 JP 2014511844 A5 JP2014511844 A5 JP 2014511844A5 JP 2014501659 A JP2014501659 A JP 2014501659A JP 2014501659 A JP2014501659 A JP 2014501659A JP 2014511844 A5 JP2014511844 A5 JP 2014511844A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
polypeptide
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014501659A
Other languages
English (en)
Japanese (ja)
Other versions
JP6130350B2 (ja
JP2014511844A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/055830 external-priority patent/WO2012131053A1/en
Publication of JP2014511844A publication Critical patent/JP2014511844A/ja
Publication of JP2014511844A5 publication Critical patent/JP2014511844A5/ja
Application granted granted Critical
Publication of JP6130350B2 publication Critical patent/JP6130350B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014501659A 2011-03-30 2012-03-30 TNFαに対する単一ドメイン抗体で免疫障害を処置する方法 Active JP6130350B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161469388P 2011-03-30 2011-03-30
US61/469,388 2011-03-30
PCT/EP2012/055830 WO2012131053A1 (en) 2011-03-30 2012-03-30 Methods of treating immune disorders with single domain antibodies against tnf-alpha

Publications (3)

Publication Number Publication Date
JP2014511844A JP2014511844A (ja) 2014-05-19
JP2014511844A5 true JP2014511844A5 (https=) 2015-04-23
JP6130350B2 JP6130350B2 (ja) 2017-05-17

Family

ID=45952510

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014501659A Active JP6130350B2 (ja) 2011-03-30 2012-03-30 TNFαに対する単一ドメイン抗体で免疫障害を処置する方法

Country Status (6)

Country Link
JP (1) JP6130350B2 (https=)
KR (1) KR20140018299A (https=)
CN (2) CN106039306A (https=)
AU (1) AU2012237287B2 (https=)
MX (1) MX361242B (https=)
WO (1) WO2012131053A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SG10201805064SA (en) 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2758434A2 (en) * 2011-09-23 2014-07-30 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Anti-tumor necrosis factor-alpha agents and uses thereof
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
SG11201706840WA (en) 2015-03-31 2017-09-28 Vhsquared Ltd Peptide construct having a protease-cleavable linker
CA3255406A1 (en) 2015-03-31 2025-07-03 Sorriso Pharmaceuticals, Inc. Tnf-alpha binding polypeptides
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2017201493A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single chain variable fragment cd3 binding proteins
EP3493844A4 (en) * 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US20180126000A1 (en) 2016-06-02 2018-05-10 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
AU2017363300A1 (en) 2016-11-23 2019-06-20 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
WO2018098356A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
CN107674122A (zh) * 2016-12-28 2018-02-09 天津天锐生物科技有限公司 一种识别人血清白蛋白的单域抗体
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELIN BINDING PROTEINS
WO2018209304A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
BR112020010694A2 (pt) 2017-12-01 2020-11-10 Abbvie Inc. agonista de receptor de glicocorticoides e imunoconjugados do mesmo
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
AR118191A1 (es) * 2019-02-28 2021-09-22 Celltrion Inc MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
AU2020275002A1 (en) 2019-05-14 2021-12-23 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
US12559552B2 (en) 2019-06-21 2026-02-24 Sorriso Pharmaceuticals, Inc. IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides
KR20220063148A (ko) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. 조성물
CA3144567A1 (en) 2019-06-21 2020-12-24 Scott Crowe Polypeptides
CN115768463A (zh) 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法
CN120463762A (zh) 2021-08-26 2025-08-12 映恩生物科技(上海)有限公司 一种甾体化合物及其缀合物
CN114591432B (zh) * 2022-03-25 2023-10-31 南京融捷康生物科技有限公司 抗TNFα的单域抗体及其用途
KR20250075632A (ko) * 2022-09-21 2025-05-28 인매진 피티이. 엘티디. TNFα 및 IL-23을 표적으로 하는 항체 및 이의 용도
AU2024334289A1 (en) 2023-08-25 2026-04-09 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
WO1992008802A1 (en) 1990-10-29 1992-05-29 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
CA2108451A1 (en) 1991-04-26 1992-10-27 Beverley J. Randle Novel antibodies, and methods for their use
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
PT627940E (pt) 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20030020733A1 (en) 2001-07-24 2003-01-30 Yin Memphis Zhihong Computer display having selective area magnification
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
BRPI0414714A (pt) 2003-09-24 2006-11-21 Pasteur Institut polinucleotìdeo purificado, vetor, célula hospedeira, construto de fusão de polipeptìdeo, métodos de inibir a rota de sinalização de nf-capab, de interromper a oligomerização de nemo, e, de identificar polipeptìdeos que modulam a oligomerização de nemo, e, uso de uma quantidade eficaz de uma composição
US8188223B2 (en) * 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
BRPI0919879A2 (pt) * 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
CA2738243C (en) * 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules

Similar Documents

Publication Publication Date Title
JP2014511844A5 (https=)
US10442857B2 (en) Anti-IL-17 antibodies
AU2010225951B2 (en) Pharmaceutical formulation containing improved antibody molecules
JP7357038B2 (ja) 改善されたtnf結合因子
CN103254310B (zh) 改良的抗体分子
AU2012285786B2 (en) TNF -alpha antigen- binding proteins with increased FcRn binding
AU2017319318B2 (en) Anti-CD3 antibody formulations
AU2018200221A1 (en) Polypeptide constructs and uses thereof
JP2011514150A5 (https=)
TW201043263A (en) Stable high protein concentration formulations of human anti-TNF-alpha-antibodies
JP2020502996A5 (https=)
JP2017528132A (ja) Il−23a及びtnf−アルファを標的とする化合物ならびにその使用
JP2022507741A5 (https=)
JP2012524071A5 (https=)
JP2014237671A5 (https=)
CA2898262A1 (en) Tnf-alpha antigen-binding proteins
CN106039306A (zh) 使用针对TNFα的单结构域抗体治疗免疫病症的方法
RU2007142444A (ru) Улучшенные нанотела против фактора некроза опухоли-альфа
JP2011518857A5 (https=)
JP2020517671A5 (https=)
JP2017524675A5 (https=)
CN114127108A (zh) Il-17拮抗剂治疗自身免疫疾病的方法
TW202241505A (zh) 抗il-17抗體治療自體免疫性疾病和炎症的方法
HK40120136A (zh) 针对警报素的双特异性结合蛋白及其用途
HK1225956A1 (en) Methods of treating immune disorders with single domain antibodies against tnf-alpha